Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies

BACKGROUND: The combination of rituximab and 2-CdA is an effective therapy for B-cell tumors. However, the molecular mechanisms and enzymatic pathways involved in the interaction between the two agents are not fully understood. In this study, we provide molecular evidence for positive interaction be...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Katib, Ayad M, Aboukameel, Amro, Ebrahim, AbdulShukkur, Beck, Frances WJ, Tekyi-Mensah, Samuel E, Raufi, Ali, Ahmed, Yasin, Mandziara, Mary, Kafri, Zyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417330/
https://www.ncbi.nlm.nih.gov/pubmed/25937997
http://dx.doi.org/10.1186/2162-3619-3-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417330/
https://www.ncbi.nlm.nih.gov/pubmed/25937997
http://dx.doi.org/10.1186/2162-3619-3-31

Ejemplares similares